Published in Eur J Biochem on August 15, 1992
Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V. Proc Natl Acad Sci U S A (1994) 1.51
Physiological anticoagulation. Resistance to activated protein C and venous thromboembolism. J Clin Invest (1994) 1.28
High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C. J Clin Invest (1999) 1.21
Protein C anticoagulant and cytoprotective pathways. Int J Hematol (2012) 1.14
Protein C activation on endothelial cells by prothrombin activation products generated in situ: meizothrombin is a better protein C activator than alpha-thrombin. Biochem J (1996) 0.85
Conformational changes in activated protein C caused by binding of the first epidermal growth factor-like module of protein S. Biochem J (2000) 0.85
Characterization of mini-protein S, a recombinant variant of protein S that lacks the sex hormone binding globulin-like domain. Biochem J (1998) 0.85
Models of the serine protease domain of the human antithrombotic plasma factor activated protein C and its zymogen. Protein Sci (1994) 0.84
Structural investigation of the A domains of human blood coagulation factor V by molecular modeling. Protein Sci (1998) 0.84
Binding of anticardiolipin antibodies to protein C via beta2-glycoprotein I (beta2-GPI): a possible mechanism in the inhibitory effect of antiphospholipid antibodies on the protein C system. Clin Exp Immunol (1998) 0.81
Molecular mechanisms of activated protein C resistance. Properties of factor V isolated from an individual with homozygosity for the Arg506 to Gln mutation in the factor V gene. Biochem J (1996) 0.80
Modeling of human factor Va inactivation by activated protein C. BMC Syst Biol (2012) 0.79
Cleavage at both Arg306 and Arg506 is required and sufficient for timely and efficient inactivation of factor Va by activated protein C. Blood Coagul Fibrinolysis (2011) 0.76
Down regulation of prothrombinase by activated protein C during prothrombin activation. Thromb Haemost (2010) 0.76
Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet (1990) 6.54
Brief report: variability of thrombosis among homozygous siblings with resistance to activated protein C due to an Arg-->Gln mutation in the gene for factor V. N Engl J Med (1994) 4.00
Deficiency of protein C in congenital thrombotic disease. J Clin Invest (1981) 3.56
Protein synthesis by native chemical ligation: expanded scope by using straightforward methodology. Proc Natl Acad Sci U S A (1999) 2.87
Binding of vascular anticoagulant alpha (VAC alpha) to planar phospholipid bilayers. J Biol Chem (1990) 2.72
Oral contraceptives and the risk of venous thrombosis. N Engl J Med (2001) 2.57
Tissue plasminogen activator (tPA) deficiency exacerbates cerebrovascular fibrin deposition and brain injury in a murine stroke model: studies in tPA-deficient mice and wild-type mice on a matched genetic background. Arterioscler Thromb Vasc Biol (1999) 2.56
The role of phospholipid and factor VIIIa in the activation of bovine factor X. J Biol Chem (1981) 2.39
The role of phospholipids and factor Va in the prothrombinase complex. J Biol Chem (1980) 2.39
A factor IX-deficient mouse model for hemophilia B gene therapy. Proc Natl Acad Sci U S A (1997) 2.22
Sex hormone-binding globulin as a marker for the thrombotic risk of hormonal contraceptives. J Thromb Haemost (2012) 2.09
A standard for low molecular weight heparin? Haemostasis (1989) 2.00
An alternating site sequence for oxidative phosphorylation suggested by measurement of substrate binding patterns and exchange reaction inhibitions. J Biol Chem (1977) 1.94
The adsorption of prothrombin to phosphatidylserine multilayers quantitated by ellipsometry. J Biol Chem (1983) 1.94
Human blood coagulation factor XI. Purification, properties, and mechanism of activation by activated factor XII. J Biol Chem (1977) 1.86
Plasma protein S deficiency in familial thrombotic disease. Blood (1984) 1.82
Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives. Br J Haematol (1997) 1.77
The value of G degrees for the hydrolysis of ATP. Biochim Biophys Acta (1972) 1.73
Human high molecular weight kininogen. Studies of structure-function relationships and of proteolysis of the molecule occurring during contact activation of plasma. J Biol Chem (1979) 1.72
American College of Medical Genetics consensus statement on factor V Leiden mutation testing. Genet Med (2001) 1.70
Anti-inflammatory, antithrombotic, and neuroprotective effects of activated protein C in a murine model of focal ischemic stroke. Circulation (2001) 1.67
Generation of prothrombin-converting activity and the exposure of phosphatidylserine at the outer surface of platelets. Eur J Biochem (1982) 1.61
Deficiency of protein C inhibitor in combined factor V/VIII deficiency disease. J Clin Invest (1980) 1.61
Mechanisms for the involvement of high molecular weight kininogen in surface-dependent reactions of Hageman factor. Proc Natl Acad Sci U S A (1976) 1.59
Mechanism of action of human activated protein C, a thrombin-dependent anticoagulant enzyme. Blood (1982) 1.58
The binding and cleavage characteristics of human Hageman factor during contact activation. A comparison of normal plasma with plasmas deficient in factor XI, prekallikrein, or high molecular weight kininogen. J Clin Invest (1977) 1.55
Different effects of oral contraceptives containing different progestogens on protein S and tissue factor pathway inhibitor. J Thromb Haemost (2007) 1.55
Activation of a pro-enzyme by a stoichiometric reaction with another protein. The reaction between prothrombin and staphylocoagulase. Biochim Biophys Acta (1975) 1.53
Activation of rabbit Hageman factor by homogenates of cultured rabbit endothelial cells. J Clin Invest (1980) 1.53
Inherited protein C deficiency and coumarin-responsive chronic relapsing purpura fulminans in a newborn infant. Lancet (1983) 1.53
Proteolytic inactivation of human factor VIII procoagulant protein by activated human protein C and its analogy with factor V. Blood (1984) 1.52
Inhibition of thrombus formation by activated recombinant protein C in a primate model of arterial thrombosis. Circulation (1990) 1.52
Role of high-molecular-weight kininogen in surface-binding and activation of coagulation Factor XI and prekallikrein. Proc Natl Acad Sci U S A (1977) 1.52
Contribution of platelet-derived factor Va to thrombin generation on immobilized collagen- and fibrinogen-adherent platelets. Thromb Haemost (2001) 1.51
Binding of protein S to factor Va associated with inhibition of prothrombinase that is independent of activated protein C. J Biol Chem (1993) 1.51
Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: a cross-over study. Thromb Haemost (2000) 1.49
Antithrombotic effects of combining activated protein C and urokinase in nonhuman primates. Circulation (1991) 1.47
Plasma glucosylceramide deficiency as potential risk factor for venous thrombosis and modulator of anticoagulant protein C pathway. Blood (2001) 1.46
Role of surface in surface-dependent activation of Hageman factor (blood coagulation factor XII). Proc Natl Acad Sci U S A (1978) 1.46
Effect of hirudin vs heparin on haemostatic activity in patients with acute coronary syndromes; the GUSTO-IIb haemostasis substudy. Eur Heart J (2002) 1.43
A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways. Thromb Haemost (2000) 1.43
Prognostic value of protein C concentrations in neutropenic patients at high risk of severe septic complications. Crit Care Med (2000) 1.40
The inhibition of blood coagulation by heparins of different molecular weight is caused by a common functional motif--the C-domain. J Thromb Haemost (2003) 1.39
Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis". J Clin Invest (1996) 1.39
Impairments of the protein C system and fibrinolysis in infection-associated stroke. Stroke (1996) 1.38
The biochemistry and pathophysiology of the contact system of plasma. Adv Immunol (1982) 1.34
A double-blind trial of long-term anticoagulant treatment after myocardial infarction. Acta Med Scand (1967) 1.34
Contributions of human platelets to the proteolytic activation of blood coagulation factors XII and XI. Blood (1981) 1.34
Isolation and partial purification of a novel anticoagulant from arteries of human umbilical cord. Eur J Biochem (1985) 1.33
Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis: a randomized cross-over study of two low-dose oral contraceptives. Thromb Haemost (2000) 1.32
Human factor XII (Hageman factor). Methods Enzymol (1976) 1.31
Protein C, an antithrombotic protein, is reduced in hospitalized patients with intravascular coagulation. Blood (1982) 1.30
Factor Xa induces cytokine production and expression of adhesion molecules by human umbilical vein endothelial cells. J Immunol (1998) 1.28
Comparison of anticoagulant and procoagulant activities of stimulated platelets and platelet-derived microparticles. Blood (1991) 1.28
Clustering of lipid-bound annexin V may explain its anticoagulant effect. J Biol Chem (1992) 1.27
Activated protein C stimulates the fibrinolytic activity of cultured endothelial cells and decreases antiactivator activity. Proc Natl Acad Sci U S A (1985) 1.27
Surface and fluid phase activities of two forms of activated Hageman factor produced during contact activation of plasma. J Exp Med (1978) 1.26
Protein S binds to and inhibits factor Xa. Proc Natl Acad Sci U S A (1994) 1.25
Tight binding of adenine nucleotides to beef-heart mitochondrial ATPase. Biochim Biophys Acta (1973) 1.23
Activated protein C resistance caused by Arg506Gln mutation in factor Va. Lancet (1994) 1.23
[Autopsy in the middle ages]. Ned Tijdschr Geneeskd (1975) 1.22
The phosphorylation potential generated by respiring mitochondria. Biochim Biophys Acta (1973) 1.22
Peptide bond cleavages and loss of functional activity during inactivation of factor Va and factor VaR506Q by activated protein C. J Biol Chem (1995) 1.22
Laboratory control of oral anticoagulants. Definition of therapeutic range in terms of different thromboplastin preparations. Thromb Diath Haemorrh (1970) 1.20
Activation of human prothrombin by stoichiometric levels of staphylocoagulase. J Biol Chem (1983) 1.20
The role of activated human platelets in prothrombin and factor X activation. Blood (1985) 1.19
Coagulation factors and the protein C system as determinants of thrombin generation in a normal population. J Thromb Haemost (2007) 1.17
Antithrombotic effects of thrombin-induced activation of endogenous protein C in primates. J Clin Invest (1993) 1.17
The frequency of type I heterozygous protein S and protein C deficiency in 141 unrelated young patients with venous thrombosis. Thromb Haemost (1988) 1.17
Effects of protein S and factor Xa on peptide bond cleavages during inactivation of factor Va and factor VaR506Q by activated protein C. J Biol Chem (1995) 1.17
Prothrombin activation by an activator from the venom of Oxyuranus scutellatus (Taipan snake). J Biol Chem (1986) 1.17
Direct detection of activated protein C in blood from human subjects. Blood (1992) 1.17
Quantitation of infarct size in man by means of plasma enzyme levels. Br Heart J (1975) 1.17
Blood coagulation factor Va abnormality associated with resistance to activated protein C in venous thrombophilia. Blood (1994) 1.16
Alteration of fibrin network by activated protein C. Blood (1994) 1.16
Mechanism of protein C-dependent clot lysis: role of plasminogen activator inhibitor. Blood (1986) 1.15
Venous thrombosis and changes of hemostatic variables during cross-sex hormone treatment in transsexual people. J Clin Endocrinol Metab (2003) 1.14
Protein C supports platelet binding and activation under flow: role of glycoprotein Ib and apolipoprotein E receptor 2. J Thromb Haemost (2008) 1.13
Thrombophilic factors are not the leading cause of thrombosis in Behçet's disease. Ann Rheum Dis (2004) 1.13